2096 Stock Overview
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China.
Simcere Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$8.03|
|52 Week High||HK$12.02|
|52 Week Low||HK$6.45|
|1 Month Change||-13.47%|
|3 Month Change||-18.31%|
|1 Year Change||7.50%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-26.87%|
Recent News & Updates
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18
The board of Simcere Pharmaceutical Group Limited ( HKG:2096 ) has announced that it will pay a dividend of HK$0.18 per...
|2096||HK Pharmaceuticals||HK Market|
Return vs Industry: 2096 exceeded the Hong Kong Pharmaceuticals industry which returned -36.4% over the past year.
Return vs Market: 2096 exceeded the Hong Kong Market which returned -19.7% over the past year.
|2096 Average Weekly Movement||5.8%|
|Pharmaceuticals Industry Average Movement||6.0%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.9%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 2096 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 2096's weekly volatility (6%) has been stable over the past year.
About the Company
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company’s principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection.
Simcere Pharmaceutical Group Fundamentals Summary
|2096 fundamental statistics|
Is 2096 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2096 income statement (TTM)|
|Cost of Revenue||CN¥1.08b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.57|
|Net Profit Margin||30.14%|
How did 2096 perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Is 2096 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2096?
Other financial metrics that can be useful for relative valuation.
|What is 2096's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2096's PE Ratio compare to its peers?
|2096 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
3320 China Resources Pharmaceutical Group
867 China Medical System Holdings
570 China Traditional Chinese Medicine Holdings
512 Grand Pharmaceutical Group
2096 Simcere Pharmaceutical Group
Price-To-Earnings vs Peers: 2096 is expensive based on its Price-To-Earnings Ratio (12.2x) compared to the peer average (7.9x).
Price to Earnings Ratio vs Industry
How does 2096's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 2096 is expensive based on its Price-To-Earnings Ratio (12.2x) compared to the Hong Kong Pharmaceuticals industry average (7.9x)
Price to Earnings Ratio vs Fair Ratio
What is 2096's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12.2x|
|Fair PE Ratio||12.8x|
Price-To-Earnings vs Fair Ratio: 2096 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the estimated Fair Price-To-Earnings Ratio (12.8x).
Share Price vs Fair Value
What is the Fair Price of 2096 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2096 (HK$8.03) is trading below our estimate of fair value (HK$22.44)
Significantly Below Fair Value: 2096 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Simcere Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2096's forecast earnings growth (1% per year) is below the savings rate (1.6%).
Earnings vs Market: 2096's earnings (1% per year) are forecast to grow slower than the Hong Kong market (17.2% per year).
High Growth Earnings: 2096's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2096's revenue (19.8% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 2096's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2096's Return on Equity is forecast to be low in 3 years time (16.3%).
Discover growth companies
How has Simcere Pharmaceutical Group performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2096 has a high level of non-cash earnings.
Growing Profit Margin: 2096's current net profit margins (30.1%) are higher than last year (14.8%).
Past Earnings Growth Analysis
Earnings Trend: 2096's earnings have grown significantly by 22.7% per year over the past 5 years.
Accelerating Growth: 2096's earnings growth over the past year (125.1%) exceeds its 5-year average (22.7% per year).
Earnings vs Industry: 2096 earnings growth over the past year (125.1%) exceeded the Pharmaceuticals industry 15.2%.
Return on Equity
High ROE: 2096's Return on Equity (23.2%) is considered high.
Discover strong past performing companies
How is Simcere Pharmaceutical Group's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2096's short term assets (CN¥5.0B) exceed its short term liabilities (CN¥3.1B).
Long Term Liabilities: 2096's short term assets (CN¥5.0B) exceed its long term liabilities (CN¥634.6M).
Debt to Equity History and Analysis
Debt Level: 2096 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2096's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 2096's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 2096's interest payments on its debt are well covered by EBIT (91.1x coverage).
Discover healthy companies
What is Simcere Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2096's dividend (2.16%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.87%).
High Dividend: 2096's dividend (2.16%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.33%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 2096's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 2096's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (26%), 2096's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 2096 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jinsheng Ren (60 yo)
Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and has been its Chairman and Chief Executive Officer since November 19, 2019. Mr. Ren has been Executive Director of Simcere Pha...
Experienced Management: 2096's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: 2096's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Simcere Pharmaceutical Group Limited's employee growth, exchange listings and data sources
- Name: Simcere Pharmaceutical Group Limited
- Ticker: 2096
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$22.366b
- Shares outstanding: 2.65b
- Website: https://www.simcere.com
Number of Employees
- Simcere Pharmaceutical Group Limited
- No. 699-18, Xuanwu Road
- Xuanwu District
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/19 00:00|
|End of Day Share Price||2022/08/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.